Revvity Signals || Signals One™

EDITORIAL SECTION

  • STRATEGY

    Smarter Pharma

    Quality management systems QMS are the backbone of pharmaceutical manufacturing ensuring safe products

  • EXPERT Talk

    Compliance to Competitive Advantage in Pharma Supply

    Compliance gets you through an audit Resilience gets medicines to patients on the day something unexpected happens The DSCSAs enhanced requirements took effect November but real interoperability required three more rounds of accommodation phased implementation with the smalldispenser

KNOWLEDGE BANK

  • Articles

    Efficiency in Bioprocessing: Unveiling Upstream and Downstream Operations

    Bioprocessing plays a crucial role in the pharmaceutical biotechnology and healthcare industries ensuring the efficient production of biologics vaccines and other biobased products

    Clinical Trials: Failures and Challenges on the Path to Treating Alzheimer’s

    Alzheimers disease AD is a neurodegenerative disorder with symptoms of memory loss and cognitive disability Typically it begins with mild symptoms that progress to become more severe AD is the th leading cause of death in the United States among people or older In million Americans suffered from AD and this is expected to rise to million by

    How to Mitigate Operational Risks in the Pharma Industry?

    The operation of the pharmaceutical industry has significant risks with the most probable being operational risks These risks include supply chain interruption regulatory non compliance product defects technological disruption The development of strategies to avoid compromise in operations remains paramount not only in protecting the customers from harm or receiving

    Real-World Evidence in Pharmaceutical Drug Development

    For most of the past halfcentury the randomised controlled trial has been the undisputed gatekeeper of pharmaceutical value It remains the gold standard for establishing causality and nothing in this article suggests otherwise Yet the controlled trial answers a narrow question under artificial conditions does a drug work in a carefully selected population managed by expert investigators over a fix...

    Access to Affordable Medicines: A Persistent Challenge for Europe

    The problem of affordable medicines has been topical in Europe for many years Despite the fact that there are well developed health units in many regions of the world and particularly in this continent the health challenges of the population have not been fully met especially in access to affordable basic medicines This problem is relevant not only to the patients but also to the stability of heal...

    From Static PDFs to Usable Digital Forms in Pharmaceutical Operations

    Walk through the quality compliance or operations function of almost any pharmaceutical manufacturer and youll find PDF forms everywhere from deviation reports change controls and training records to supplier questionnaires audit checklists and equipment logs Many of these documents exist as PDF files but functionally still behave like paper Someone prints them fills them in by hand

TOP ARTICLES

  • 3

    Real-World Evidence in Pharmaceutical Drug Development

    Lakshmi

    Real-world evidence has moved from post-marketing footnote to strategic currency in pharmaceutical drug development. With regulators on both sides of the Atlantic now accepting registry, claims and he...

press releases Read more...

Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia

Cardiff Oncology Inc a clinicalstage biotechnology company leveraging PLK inhibition to develop novel cancer therapies today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia

Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer

Geneos Therapeutics a clinical stage biotherapeutics company focused on the development of neoantigenbased personalized immunotherapy for cancer PIC today announced the initiation of its Phase randomized clinical trial NCT in patients with highrisk hepatocellular carcinoma HCC liver cancer

Medicovestor Announces FDA Fast Track Designation for MC001, Its First-in-Class Chemoimmunotherapy ADC for Pancreatic Cancer

Medicovestor Inc today announced that the US Food and Drug Administration FDA has granted Fast Track designation to MC its lead investigational firstinclass chemoimmunotherapy antibodydrugconjugate ADC for pancreatic cancer

Orogen Therapeutics Announces Selection of Two Development Candidates for Immune Diseases, Potential Best-in-Class Oral IL-17 and JAK1/TYK2 Small Molecule Inhibitors

Orogen Therapeutics Inc announced the selection of two development candidates DCs ORO and ORO potential bestinclass oral small molecule inhibitors of IL and JAKTYK respectively Both DCs have completed extensive nonclinical studies to demonstrate attractive

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

Pharma Manufacturing & Automation Convention 2026

Novotel Hyderabad Airport, Ind...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

LATEST NEWS Read more...

AI Proteins Announces Research Collaboration and License Agreement With Astellas Pharma to Discover and Develop Novel Miniprotein-Based Therapeutics Valued at Over $400 Million

AI Proteins Inc a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC an affiliate of Astellas Pharma Inc TSE to discove...

Okomera Announces Trade Agreement with Servier to Use Tumor Miniaturization Technology in Cancer Research

Okomera a TechBio company that personalizes cancer management with its technology combining minivatars tumor microfluidics and AI imaging today announced the signing of a commercial agreement with Servier an independent international pharmaceutical group

ScionxBio Announces Collaboration to Develop Long-Acting xRNA Therapeutics

ScionxBio a privately held preclinicalstage biotechnology company pioneering nextgeneration mRNA therapeutics distinguished by their extended durability profile today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi

Takara Bio USA Partners with SPT Labtech to Deliver Automation-Ready NGS Library Preparation Technologies

Takara Bio USA Inc a wholly owned subsidiary of Takara Bio Inc and SPT Labtech today announced their partnership to deliver validated automated library preparation workflows that combine Takara Bio nextgeneration sequencing NGS library preparation chemistries with SPT Labtechs firefly liquid handlin...

AtomVie Global Radiopharma Announces Strategic Partnership with Jubilant Radiopharma to Strengthen Logistics and Distribution in Clinical Trials

AtomVie Global Radiopharma a global contract developer and manufacturer CDMO for radiopharmaceuticals today announced a strategic partnership with Jubilant DraxImage Inc operating as Jubilant Radiopharma Jubilant Radiopharma to provide logistics approval and lastmile distribution services to support

Transcripta Bio Announces Research Collaboration to Advance Discovery of New ALS Treatments

Transcripta Bio an AIpowered drug discovery company focused on neurological and neuromuscular diseases today announced a research collaboration and licensing agreement with Mayo Clinic centered on amyotrophic lateral sclerosis ALS a fatal neurodegenerative disease with few effective treatments